S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Laser breakthrough could send stock soaring 2,467% (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Laser breakthrough could send stock soaring 2,467% (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Laser breakthrough could send stock soaring 2,467% (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Laser breakthrough could send stock soaring 2,467% (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?

Grifols (GRFS) Price Target & Analyst Ratings

$8.24
-0.37 (-4.30%)
(As of 05/31/2023 ET)
Compare
Today's Range
$8.13
$8.51
50-Day Range
$6.85
$9.01
52-Week Range
$5.71
$13.10
Volume
473,182 shs
Average Volume
938,248 shs
Market Capitalization
$5.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.52

Grifols Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 7 Analyst Ratings

Consensus Analyst Price Target

N/A

TypeCurrent
6/1/22 to 6/1/23
1 Month Ago
5/2/22 to 5/2/23
3 Months Ago
3/3/22 to 3/3/23
1 Year Ago
6/1/21 to 6/1/22
Consensus Rating
Moderate Buy
Moderate Buy
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Predicted UpsideN/AN/AN/AN/A
Get Grifols Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.


GRFS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GRFS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Grifols Stock vs. The Competition

TypeGrifolsMedical CompaniesS&P 500
Consensus Rating Score
2.57
2.66
2.49
Consensus RatingModerate BuyBuyHold
Predicted Upside1,269.28% Upside200.47% Upside
News Sentiment RatingVery Positive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/12/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight
2/16/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight
2/6/2023AlphaValue
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeBuy
1/18/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
11/25/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral ➝ Neutral
10/25/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold€16.00 ➝ €10.00
9/14/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target€11.50 ➝ €10.30
7/15/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy€20.15 ➝ €20.30
(Data available from 5/31/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












GRFS Price Target - Frequently Asked Questions

What is Grifols's consensus rating?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Grifols stock is Moderate Buy based on the current 3 hold ratings and 4 buy ratings for GRFSthe . Learn more on GRFS's analyst rating history.

Do Wall Street analysts like Grifols more than its competitors?

Analysts like Grifols less than other Medical companies. The consensus rating for Grifols is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how GRFS compares to other companies.

Is Grifols being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, Grifols's stock had 1 upgrade and 1 downgrade by analysts.

What analysts cover Grifols?

Grifols has been rated by Morgan Stanley in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:GRFS) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -